Comprehensive Snapshot for Neglected Tropical Diseases Diagnosis Market, Including Country and Segment Analysis in Brief.
Industry: Healthcare
Delivery Timelines: Please Contact Sales
Published Date: June-2025
Format: PPT*, PDF, EXCEL
Number of Pages: 195
ID: PMRREP35377
The global neglected tropical diseases diagnosis market size is predicted to reach US$ 10,204.8 Mn in 2032 from US$ 7,600.0 Mn in 2025. It will likely witness a CAGR of around 4.3% in the forecast period between 2025 and 2032.
Neglected tropical diseases (NTDs) persist as a silent but devastating public health challenge, primarily affecting underserved and impoverished communities. These diseases remain underreported and underdiagnosed, mainly due to the limited access to novel diagnostic tools and the complexity of their detection in endemic regions. Accurate and timely diagnosis is required to break the chains of transmission, enable targeted treatment, and update control strategies. Recent technological developments and renewed research efforts are transforming this field, providing new hope through field-adapted, sensitive, and rapid diagnostic methods.
Key Industry Highlights
|
Global Market Attribute |
Key Insights |
|
Neglected Tropical Diseases Diagnosis Market Size (2025E) |
US$ 7,600.0 Mn |
|
Market Value Forecast (2032F) |
US$ 10,204.8 Mn |
|
Projected Growth (CAGR 2025 to 2032) |
4.3% |
|
Historical Market Growth (CAGR 2019 to 2024) |
3.2% |
Surging government initiatives are envisioned to boost the neglected tropical diseases diagnosis market growth in the foreseeable future, finds Persistence Market Research. India’s Ministry of Health, for instance, enhanced its Kala-Azar elimination campaign in 2023 by implementing mobile diagnostic units equipped with geo-tagging tools and Rapid Diagnostic Tests (RDTs) across endemic blocks in Jharkhand and Bihar. This resulted in a 35% surge in case detection compared to 2022. It also propelled the mapping of residual transmission pockets, enabling targeted spraying and vector control.
In Ethiopia, the government’s 2024 integrated NTD master plan also focused on a shift from vertical disease programs to integrated diagnostic approaches. It has already prompted the launch of community-based surveys using multiplex immunoassay platforms to simultaneously test for lymphatic filariasis, soil-transmitted helminths, and schistosomiasis. These efforts are mainly supported by the Federal Ministry of Health in collaboration with the END Fund. These have proven significant in transitioning from mass drug administration to precision treatment models.
Limited resources and attention are likely to continue hinder progress in diagnosing neglected tropical diseases. It is expected to be evident in regions where overlapping public health priorities dilute funding and political will. During the 2023 Sudan conflict, for example, multiple NTD surveillance programs were disrupted as laboratory facilities were repurposed for emergency and trauma care. Diagnostic efforts for schistosomiasis and visceral leishmaniasis halted in Gedaref and Blue Nile states, thereby resulting in underreporting and treatment delays.
Various endemic countries often face a significant shortage of trained diagnostic personnel, which is overlooked in budget allocations. In 2024, a World Health Organization (WHO)-supported assessment in Mozambique found that more than 60% of rural health posts lacked staff capable of performing even basic thick smear or Kato-Katz procedures for malaria and schistosomiasis, respectively. While diagnostics exist, the lack of human resources has turned reagents and equipment into idle inventory in multiple provinces. This shortage also limits the expansion of physician office diagnostic testing, which often help decentralize NTD diagnosis.
Research and development activities are poised to create new growth avenues through 2032. A significant breakthrough has been the innovation of point-of-care molecular diagnostics, which blend sensitivity with field adaptability. In 2024, for example, the London School of Hygiene & Tropical Medicine developed a battery-operated, handheld PCR device to detect Leishmania donovani DNA in 45 minutes. Field trials in Bihar, India demonstrated that the device boosted early case detection by 40%, enabling timely treatment before the onset of severe symptoms.
Another key opportunity arises from the use of Artificial Intelligence (AI) and machine learning algorithms to analyze diagnostic data and images. The African Research Consortium recently introduced an AI-powered smartphone app that automatically interprets microscopy slides for schistosomiasis eggs. It allows community health workers in remote villages across Tanzania to conduct accurate screenings without special training. This democratization of diagnostics is expected to improve screening coverage in hard-to-reach areas.
By disease, the market is divided into dengue, rabies, yaws, chikungunya, leprosy, lymphatic filariasis, Buruli ulcer, echinococcosis, taeniasis/cysticercosis, dracunculiasis, foodborne trematodiases, Chagas disease (American trypanosomiasis), African trypanosomiasis, soil-transmitted helminth infections, onchocerciasis, scabies and other ectoparasites, schistosomiasis, snakebite envenoming, and leishmaniasis. Among these, soil-transmitted helminth infections are predicted to hold a share of 23.4% in 2025. This is due to rising global emphasis on precision public health and high demand for data-driven deworming programs. Conventional Mass Drug Administration (MDA) campaigns are now being evaluated for their sustainability, creating a rapid shift toward diagnostics-led interventions.
Dracunculiasis, on the other hand, will likely showcase a steady CAGR from 2025 to 2032. It is gaining renewed focus due to the urgent requirement for improved surveillance tools in the last mile of eradication. Early and precise detection has become significant to interrupt the final chains of transmission, specifically in Mali, Ethiopia, South Sudan, and Chad. Genetic diagnostics, a promising tool in rare disease treatment, are further being investigated to confirm dracunculiasis cases in ambiguous human and animal presentations.
Based on diagnostic method, the market is bifurcated into conventional and molecular/modern. Out of these, the conventional segment is speculated to account for 50.4% of the neglected tropical diseases diagnosis market share in 2025. It is primarily due to their superior compatibility, ease of use, and affordability across low-resource settings where NTDs are most prevalent. For instance, microscopy continues to be the frontline diagnostic tool for leishmaniasis and schistosomiasis, mainly in rural clinics without access to molecular diagnostics.
Molecular/modern methods are expected to witness a considerable CAGR from 2025 to 2032. This is owing to their ability to detect asymptomatic and low-intensity infections that conventional methods often miss. This is specifically relevant in regions transitioning from control to elimination, where traditional serology or microscopy lacks the sensitivity required for accurate surveillance. A 2023 study in Cambodia, for example, piloted a LAMP assay to detect transmission hotspots that were previously undetected by Kato-Katz stool smear, accelerating changes in intervention strategies.
The diagnosis of NTDs is often overlooked in mainstream healthcare settings across North America, despite the prevalence of toxocariasis, cysticercosis, and Chagas disease among underserved populations. Access to diagnostic remains limited, backed by awareness, economic, and regulatory-related barriers. A 2023 study published by the Centers for Disease Control and Prevention (CDC) stated that less than 1% of suspected Chagas cases among immigrants from Latin America were formally diagnosed in the U.S. It was due to the limited availability of confirmatory testing outside specialized centers and lack of routine screening protocols.
The U.S. neglected tropical diseases diagnosis market will likely outpace Canada through 2032 as efforts to enhance diagnostic infrastructure are seeing decent growth. These are mainly augmented by public and academic health collaborations. Baylor College of Medicine’s National School of Tropical Medicine, for example, recently introduced a mobile outreach program in Arizona and Texas to perform POC screening for strongyloidiasis and Chagas disease using rapid serological tests and dried blood spots. This model is considered one of the few structured efforts addressing NTDs in U.S. domestic settings.
In the Middle East and Africa, Africa is projected to remain at the forefront of growth, backed by significant reliance on community-based and point-of-care diagnostic methods. It is primarily due to limited access to centralized laboratory infrastructure. In countries such as Ethiopia and Uganda, diagnostic efforts are mainly decentralized, with village health teams and mobile health units playing significant roles in early detection. This approach has been successful in the detection of lymphatic filariasis and schistosomiasis, especially in remote areas.
Local innovation is also becoming increasingly important for smooth detection and prevention. For example, Senegal’s Institut Pasteur has already launched a solar-powered, cost-effective molecular diagnostic unit made for use in rural clinics. The system was first tested in 2023, and it utilizes Loop-Mediated Isothermal Amplification (LAMP) to detect human African trypanosomiasis and leishmaniasis. Similar developments are expected to offer higher sensitivity compared to conventional microscopy, reducing reliance on imported tests.
In 2025, Asia Pacific is estimated to account for a share of approximately 32.7%. This is attributed to a rising focus on integrating diagnostics into primary healthcare systems and local manufacturing initiatives. Countries such as Vietnam and Thailand have taken a proactive step in embedding NTD screening in national health programs, mainly for leprosy and soil-transmitted helminths. A 2023 initiative in Vietnam led by the National Institute of Malariology, Parasitology, and Entomology, for instance, integrated RTD for various parasitic infections into routine school health check-ups, targeting early detection among children.
Southeast Asia has been witnessing a surge in cross-border diagnostic harmonization and disease surveillance, specifically along the Mekong River basin. A trilateral project involving Thailand, Cambodia, and Laos in 2024, for instance, piloted a shared digital diagnostic reporting platform for schistosomiasis and opisthorchiasis. This initiative utilizes GPS-tagged mobile apps to track infection hotspots and feed real-time diagnostic data into national databases, enabling coordinated responses to disease outbreaks. Various domestic biotech firms are also focusing on developing in-cell ELISA kits for dengue and lymphatic filariasis to reduce dependence on imports.
The neglected tropical diseases diagnosis market is relatively underfunded and fragmented, with a limited number of companies focusing on disease-specific diagnostics owing to low commercial returns. The market is more propelled by public-private partnerships, academic collaborations, and non-profit organizations than conventional diagnostics companies. There is, however, a surging trend of diagnostic innovation emerging from research institutions in endemic countries, specifically in Southeast Asia and Africa. This is predicted to result in the development of localized solutions catering to specific regional challenges, including extreme environmental conditions.
|
Report Attribute |
Details |
|
Historical Data/Actuals |
2019 - 2024 |
|
Forecast Period |
2025 - 2032 |
|
Market Analysis Units |
Value: US$ Bn/Mn, Volume: As Applicable |
|
Geographical Coverage |
|
|
Segmental Coverage |
|
|
Competitive Analysis |
|
|
Report Highlights |
|
|
Customization and Pricing |
Available upon request |
By Disease
By Diagnostic Method
By Service Type
By End-use
By Region
To know more about delivery timeline for this report Contact Sales
The market is projected to reach US$ 7,600.0 Mn in 2025.
Surging government investments in research work and emergence of accurate tests are the key market drivers.
The market is poised to witness a CAGR of 4.3% from 2025 to 2032.
Rising integration of AI in innovative tests and increasing health awareness initiatives by non-profit organizations are the key market opportunities.
F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., and Abbott Laboratories are the key market players.
